Literature DB >> 26671985

Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.

Nicholas M Kanaan, Kristine Cox, Victor E Alvarez, Thor D Stein, Sharra Poncil, Ann C McKee.   

Abstract

Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy that develops after repetitive head injury. Several lines of evidence in other tauopathies suggest that tau oligomer formation induces neurotoxicity and that tau oligomer-mediated neurotoxicity involves induction of axonal dysfunction through exposure of an N-terminal motif in tau, the phosphatase-activating domain (PAD). Additionally, phosphorylation at serine 422 in tau occurs early and correlates with cognitive decline in patients with Alzheimer disease (AD). We performed immunohistochemistry and immunofluorescence on fixed brain sections and biochemical analysis of fresh brain extracts to characterize the presence of PAD-exposed tau (TNT1 antibody), tau oligomers (TOC1 antibody), tau phosphorylated at S422 (pS422 antibody), and tau truncated at D421 (TauC3 antibody) in the brains of 9-11 cases with CTE and cases of nondemented aged controls and AD (Braak VI) (n = 6, each). All 3 early tau markers (ie, TNT1, TOC1, and pS422) were present in CTE and displayed extensive colocalization in perivascular tau lesions that are considered diagnostic for CTE. Notably, the TauC3 epitope, which is abundant in AD, was relatively sparse in CTE. Together, these results provide the first description of PAD exposure, TOC1 reactive oligomers, phosphorylation of S422, and TauC3 truncation in the tau pathology of CTE.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26671985      PMCID: PMC4891281          DOI: 10.1093/jnen/nlv001

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  71 in total

1.  Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model.

Authors:  Lee E Goldstein; Andrew M Fisher; Chad A Tagge; Xiao-Lei Zhang; Libor Velisek; John A Sullivan; Chirag Upreti; Jonathan M Kracht; Maria Ericsson; Mark W Wojnarowicz; Cezar J Goletiani; Giorgi M Maglakelidze; Noel Casey; Juliet A Moncaster; Olga Minaeva; Robert D Moir; Christopher J Nowinski; Robert A Stern; Robert C Cantu; James Geiling; Jan K Blusztajn; Benjamin L Wolozin; Tsuneya Ikezu; Thor D Stein; Andrew E Budson; Neil W Kowall; David Chargin; Andre Sharon; Sudad Saman; Garth F Hall; William C Moss; Robin O Cleveland; Rudolph E Tanzi; Patric K Stanton; Ann C McKee
Journal:  Sci Transl Med       Date:  2012-05-16       Impact factor: 17.956

2.  The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.

Authors:  Nichole E LaPointe; Gerardo Morfini; Gustavo Pigino; Irina N Gaisina; Alan P Kozikowski; Lester I Binder; Scott T Brady
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

3.  Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.

Authors:  Nicholas M Kanaan; Gerardo A Morfini; Nichole E LaPointe; Gustavo F Pigino; Kristina R Patterson; Yuyu Song; Athena Andreadis; Yifan Fu; Scott T Brady; Lester I Binder
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

Review 4.  Tau oligomers and tau toxicity in neurodegenerative disease.

Authors:  Sarah M Ward; Diana S Himmelstein; Jody K Lancia; Lester I Binder
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

5.  Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.

Authors:  Kristina R Patterson; Christine Remmers; Yifan Fu; Sarah Brooker; Nicholas M Kanaan; Laurel Vana; Sarah Ward; Juan F Reyes; Keith Philibert; Marc J Glucksman; Lester I Binder
Journal:  J Biol Chem       Date:  2011-05-06       Impact factor: 5.157

6.  Neurons may live for decades with neurofibrillary tangles.

Authors:  R Morsch; W Simon; P D Coleman
Journal:  J Neuropathol Exp Neurol       Date:  1999-02       Impact factor: 3.685

7.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

8.  Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology.

Authors:  Robert A Rissman; Wayne W Poon; Mathew Blurton-Jones; Salvatore Oddo; Reidun Torp; Michael P Vitek; Frank M LaFerla; Troy T Rohn; Carl W Cotman
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads.

Authors:  E Braak; H Braak; E M Mandelkow
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 10.  Diffuse axonal injury in brain trauma: insights from alterations in neurofilaments.

Authors:  Declan G Siedler; Meng Inn Chuah; Matthew T K Kirkcaldie; James C Vickers; Anna E King
Journal:  Front Cell Neurosci       Date:  2014-12-17       Impact factor: 5.505

View more
  43 in total

1.  Endoplasmic Reticulum Stress Modulation as a Target for Ameliorating Effects of Blast Induced Traumatic Brain Injury.

Authors:  Brandon P Lucke-Wold; Aric F Logsdon; Ryan C Turner; Jason D Huber; Charles L Rosen
Journal:  J Neurotrauma       Date:  2017-02-27       Impact factor: 5.269

2.  Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.

Authors:  Chelsea T Tiernan; Benjamin Combs; Kristine Cox; Gerardo Morfini; Scott T Brady; Scott E Counts; Nicholas M Kanaan
Journal:  Exp Neurol       Date:  2016-06-30       Impact factor: 5.330

3.  Progression of tau pathology within cholinergic nucleus basalis neurons in chronic traumatic encephalopathy: A chronic effects of neurotrauma consortium study.

Authors:  Elliott J Mufson; Sylvia E Perez; Muhammad Nadeem; Laura Mahady; Nicholas M Kanaan; Eric E Abrahamson; Milos D Ikonomovic; Fiona Crawford; Victor Alvarez; Thor Stein; Ann C McKee
Journal:  Brain Inj       Date:  2016       Impact factor: 2.311

4.  Exposure of the Amino Terminus of Tau Is a Pathological Event in Multiple Tauopathies.

Authors:  Benjamin Combs; Nicholas M Kanaan
Journal:  Am J Pathol       Date:  2017-04-14       Impact factor: 4.307

5.  Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.

Authors:  Kristine Cox; Benjamin Combs; Brenda Abdelmesih; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Neurobiol Aging       Date:  2016-07-29       Impact factor: 4.673

6.  Tau and Axonal Transport Misregulation in Tauopathies.

Authors:  Benjamin Combs; Rebecca L Mueller; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

7.  Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimer's disease.

Authors:  John D Arena; Douglas H Smith; Edward B Lee; Garrett S Gibbons; David J Irwin; John L Robinson; Virginia M-Y Lee; John Q Trojanowski; William Stewart; Victoria E Johnson
Journal:  Brain       Date:  2020-05-01       Impact factor: 13.501

8.  Production of recombinant tau oligomers in vitro.

Authors:  Benjamin Combs; Chelsea T Tiernan; Chelsey Hamel; Nicholas M Kanaan
Journal:  Methods Cell Biol       Date:  2017-07-14       Impact factor: 1.441

Review 9.  Intercellular Spread of Protein Aggregates in Neurodegenerative Disease.

Authors:  Albert A Davis; Cheryl E G Leyns; David M Holtzman
Journal:  Annu Rev Cell Dev Biol       Date:  2018-07-25       Impact factor: 13.827

10.  Tau is not necessary for amyloid-β-induced synaptic and memory impairments.

Authors:  Daniela Puzzo; Elentina K Argyrousi; Agnieszka Staniszewski; Hong Zhang; Elisa Calcagno; Elisa Zuccarello; Erica Acquarone; Mauro Fa'; Domenica D Li Puma; Claudio Grassi; Luciano D'Adamio; Nicholas M Kanaan; Paul E Fraser; Ottavio Arancio
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.